A Multicenter Prospective Clinical Study of Endoscopic Foam Sclerotherapy for Internal Hemorrhoids

Launched by XINHUA HOSPITAL, SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE · May 18, 2020

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • People are willing to sign the informed consent form of this trial.
• • People(aged 18 to 70 years) with clinical symptoms such as bleedingprolapse and so on have been diagnosed with grade I, grade II and grade III internal hemorrhoids by colonic epdoscopy;
• • People can follow short-term (3 month) and long-term (12 month) visit plans;
• • Describe symptoms objectively and actively complete the evaluation scale;
• • No allergic diseases and allergy to sclerosing drugs;
• • Non-lactating and pregnant women: patients without pregnancy plan (including the men) in 1 month after the test;
• • Did not participate in any drug trials (including this trial drug) within 3 months before the trial;
• • People with long-term use of anticoagulant drugs (such as aspirin, clopidogrel, etc.) need to be stopped for 5-7 day
• Exclusion Criteria:
• • People with severe insufficiency of heart, brain, lung and other organs, leading to inability to tolerate endoscopic treatment;
• • People with drug allergies or abnormal blood coagulation function;
• • People suffering from or combined with digestive tract diseases,such as the colon malignancyulcerative colitis or Crohn's diseaseacute diarrheaacute thrombotic internal hemorrhoids with painanal fistulaanal fissurefecal incontinence
• • Men with history of severe prostate hypertrop;
• • People with any reasons that the researchers believe can not be selected